Eudragit® FS based colonic microparticls of metoprolol tartrate

Acta Poloniae Pharmaceutica - Drug Research

Volumn 69, Issue 2, 2012, Pages 347-353

  Rasool, Fatima ^a   Ahmad, Mahmood ^a   Murtaza, Ghulam ^b   Khan, Haji M S ^a   Khan, Shujaat Ali ^a  

^a THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^b Tobe Camp University Road Abbottabad   (Pakistan)

Author keywords

Colonic tabletted microparticles; Eudragit FS; Metoprolol tartrate; Microencapsulation

Indexed keywords

EUDRAGIT; MEPRESSOR; METOPROLOL TARTRATE; UNCLASSIFIED DRUG; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; METHYLMETHACRYLATE METHACRYLIC ACID COPOLYMER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; METOPROLOL; POLYMETHACRYLIC ACID DERIVATIVE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; IN VITRO STUDY; INFRARED SPECTROSCOPY; MEMBRANE MICROPARTICLE; PH; X RAY DIFFRACTION; CHEMISTRY; COLON; DRUG FORMULATION; METABOLISM; PARTICLE SIZE; SOLUBILITY; TABLET;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; COLON; DRUG COMPOUNDING; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; METOPROLOL; PARTICLE SIZE; POLYMETHACRYLIC ACIDS; SOLUBILITY; TABLETS;

EID: 84860015067     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Basit A.W.: Drugs 65, 1991 (2005).
2. Sinha V.R., Kumria R.: Acta Pharm. 53, 41 (2003).
3. Li J., Yang L., Ferguson S.M. et al.: AAPS PharmSciTech 3, Article 33 (2002).
4. Watanabe S, Kawai H, Katsuma M, Fukui M. Colon-specific drug release system. US patent 6368629. April 9 (2002).
5. Ibekwe V.C., Khela M.K., Evans D.F., et al.: Aliment. Pharmacol. Therap. 28, 911 (2008).
6. Evans D.F., Pye G., Bramley R., Clark A.G., Dyson T.J., Hardcastle J.D.: Gut 29, 1035 (1988).
7. Marvola M.: Eur. J. Pharm. Sci. 7, 259 (1999).
8. Ibekwe B.C., Basit W.A., Parsons G.E.: AAPS Pharm Sci. 5, T3035 (2003) .
9. thedn., McGraw-Hill, New York 2005.
10. th edn. pp. 1125-1129, McGraw-Hill, Medical Publishing Division, New York 2001.
11. Aqil M., Ali A., Ahad A., Sultana Y., Najmi A.K., Saha N.: Acta Chromatogr. 19, 130 (2007).
12. Nellore R.V., Rekhi G.S., Hussain A.S., Tillman L.G., Augsburger L.L.: J. Control. Release 50, 247 (1998).
13. Gang C., Feng A., Mei-Juan Z. et al.: World J. Gastroenterol. 10, 1769 (2004).
14. Khamanga S.M., Parfitt N., Nyamuzhiwa T. et al.: Dissol. Technol. 15, 13 (2009).
15. Wieland-Berghausen S., Schote U., Frey M., Schmidt F.: J. Control. Release 85, 35 (2002).
16. Yamuda T., Onishi H., Machida Y.: J. Control. Release 75, 271 (2001).
17. Eddington N.D.: Int. J. Generic Drugs 34, 417 (2000).
18. U.S. Department of Health and Human Services. Guidance for industry: Modified release solid oral dosage forms scale-up and postapproval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. Center for drug Evaluation and Research, Food and Drug Administration. Rockville, MD 1995.
19. Eddington N.D., Marroum P., Uppoor R., Hussain A., Augsburger L.: Pharm. Res. 15, 466 (1998).
20. Rasool F., Ahmad M., Murtaza G., et al.: WASIT 63, 140 (2010).
21. USP30-NF25. The official compendium of standards. The United States Pharmacopoeial Convention, Rockville, MD 2007.
22. Kilicarslan M., Baykara T.: Int. J. Pharm. 252, 99 (2003).
23. Murtaza G., Ahamd M., Akhtar N., ET AL.: Pak. J. Pharm. Sci. 22, 291 (2009).
24. Roli J., Archna P., Sashi S.P.: Chemistry 18, 131 (2009).